Brazilian ibd study group position statement on sars-cov2 vaccination
Nenhuma Miniatura disponível
Data
2021-01-01
Autores
Queiroz, Natália Sousa Freitas
Teixeira, Fábio Vieira
Freire, Caio Cesar Furtado
Motta, Marina Pamponet
De Vasconcellos, Marcela Almeida Menezes
Chebli, Liliana Andrade
Hossne, Rogerio Saad [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.
Descrição
Palavras-chave
Como citar
Arquivos de Gastroenterologia, v. 58, n. 1, p. 2-4, 2021.